Prof. Jonathan Waxman, Oncologist
Prof. Jonathan Waxman
Oncologist
Prof. Jonathan Waxman
Oncologist
Prof. Jonathan Waxman
Oncologist
Make an appointment
Address
-
LOC - Leaders in Oncology Care
95-97 Harley Street, London, W1G 6AF
-
The Harley Street Clinic
35 Weymouth Street, London, W1G 8BJ
About Prof. Jonathan Waxman
GMC number: 2274087
Year qualified: 1975
Place of primary qualification: University of London
Prof. Jonathan Waxman is a distinguished medical specialist in the field of oncology. He trained at University College and University College Hospital, London, where he was awarded several scholarships and prizes during his undergraduate and postgraduate studies. Currently, he holds the position of Prof. of Oncology at Imperial College London and serves as a consultant to the Department of Oncology at Hammersmith Hospital. Prof. Waxman played a pivotal role in the campaign to establish the Hammersmith Cancer Centre.
In addition to his clinical duties, Prof. Waxman is the founder of the Prostate Cancer Charity, which is projected to raise £20 million in the current financial year. Before his tenure at Hammersmith Hospital, he was an Imperial Cancer Research Fund Research Fellow at St Bartholomew’s Hospital.
Prof. Waxman's primary research focus is on prostate cancer. He has an extensive publication record, having written over 400 research papers and book chapters. He is also the author of eleven medical books, a novel, a patient information book, and a legal textbook. His expertise extends to writing on healthcare policy for major newspapers.
His areas of expertise include the diagnosis and treatment of prostate, kidney, bladder, and testicular cancers, with a particular emphasis on chemotherapy for testicular cancer. Prof. Waxman has been a key figure in advancing oncology research and treatment since his appointment.
Prof. Waxman is dedicated to improving patient outcomes through both his clinical practice and his ongoing research efforts. His contributions to the field of oncology have made a significant impact on cancer treatment and patient care.